로딩 중…
StockDiggingStockDigging

Sanofi

SNY· NASDAQ
FRFR
$42.48-1.53%
2026-09-18

Financials

Valuation Metrics

Sanofi's Market Cap is $101.53B. At end of 2025 it was $136.25B. Ranked #155 of 3,121 in US market (top 5%), #47 of 1,463 on NASDAQ (top 3%), #13 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$101.53B
Revenue$55.27B
Net Income$4.47B
Total Assets$151.61B
Net Assets$81.30B
Employees76,493
Value
P/E22.70x
P/B1.25x
P/S1.84x
EV/EBITDA8.68x
FCF Yield13.10%
Profitability
ROE5.50%
ROA2.95%
Op. Margin14.80%
Revenue Growth13.42%
Earnings Growth-56.63%
Financial Health
Debt Ratio85.96%
Total Debt$27.70B
FCF$13.30B
Cash$7.46B
Current Ratio0.99x
Net Debt/EBITDA1.44x
Dividend
Div. Yield6.39%
Div. Growth14.49%
Performance
1Y Return-10.91%
1M Return-7.31%
From 52W High-19.36%
1Y MDD-21.04%
Trading
Volume2,220,321 shares
Trading Value$94M
Per Share
EPS$1.87
BPS$34.02

Company Info

CEO Belén Garijo López
Employees 76,493
HQ Paris, FR

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.